バージニアにおける胃癌の臨床試験
バージニア内の拠点で、胃癌に関する27件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- VCU Health Tappahannock Hospital, Tappahannock
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07529808Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem, Salem
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Virginia Cancer Specialists, PC, Arlington
- Virginia Oncology Associates, Chesapeake
- Virginia Cancer Specialists, PC, Fairfax
- 他7件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07392892Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Blacksburg
- Research Site, Fairfax
- Research Site, Fort Belvoir
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他5件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/13更新 · NCT07066657Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Virginia Oncology Associates, Norfolk
- Blue Ridge Cancer Care, Roanoke
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06731478A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Oncology & Hematology Associates of Southwest Virginia, Roanoke
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/21更新 · NCT07317505A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。